ChondroGene presents blood-based detection of colon, prostate cancer abstracts at ASCO

By Lisa Kerner

Charlotte, N.C., June 7 - ChondroGene Ltd.'s two abstracts presented at the American Society of Clinical Oncology Annual Meeting highlighted results of the company's work in identifying blood-based biomarkers for the detection of colorectal and prostate cancer using the Sentinel Principle to identify molecular signatures of disease in blood.

The first abstract reports results from a study in which 31 blood RNA samples were profiled to identify differentially expressed genes and subsets of genes.

A combination of five genes was then used in a blinded test of 83 samples, demonstrating an effective blood-based approach for the detection of colorectal cancer, according to a company news release.

In the second abstract, gene discovery and validation in prostate cancer are discussed.

ChondroGene is focused on developing and optimizing the design and performance parameters for its lead product, ColonSentry, for the detection of colorectal cancer from a blood sample, officials said.

Toronto-based ChondroGene uses functional genomics to enable early diagnosis and therapeutic intervention based on disease-specific biomarkers.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.